Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.
Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Goto H, Fukuno K, Kitagawa J, Yasuda I, Katsumura N, Takemura M, Takahashi T, Takami T, Moriwaki H. Hara T, et al. Among authors: kitagawa j. J Cancer Res Clin Oncol. 2009 Oct;135(10):1421-8. doi: 10.1007/s00432-009-0586-4. Epub 2009 Apr 21. J Cancer Res Clin Oncol. 2009. PMID: 19381687
Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
Kitagawa J, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Takahashi T, Shimizu M, Takami T, Moriwaki H. Kitagawa J, et al. J Cancer Res Clin Oncol. 2009 Jan;135(1):53-9. doi: 10.1007/s00432-008-0440-0. Epub 2008 Jul 1. J Cancer Res Clin Oncol. 2009. PMID: 18592269
Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Yasuda I, Katsumura N, Takahashi T, Takami T, Moriwaki H. Hara T, et al. Among authors: kitagawa j. J Cancer Res Clin Oncol. 2010 Jan;136(1):65-70. doi: 10.1007/s00432-009-0637-x. J Cancer Res Clin Oncol. 2010. PMID: 19590893 Clinical Trial.
Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.
Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J, Kanemura N, Kasahara S, Ito H, Takemura M, Saito K, Seishima M, Takami T, Moriwaki H. Yoshikawa T, et al. Among authors: kitagawa j. Eur J Haematol. 2010 Apr;84(4):304-9. doi: 10.1111/j.1600-0609.2009.01393.x. Epub 2009 Nov 7. Eur J Haematol. 2010. PMID: 19995374 Clinical Trial.
Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.
Kasahara S, Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Goto H, Fukuno K, Yamada T, Sawada M, Takahashi T, Takami T, Moriwaki H. Kasahara S, et al. Among authors: kitagawa j. Leuk Lymphoma. 2011 Apr;52(4):629-34. doi: 10.3109/10428194.2011.555024. Leuk Lymphoma. 2011. PMID: 21438831 Clinical Trial.
A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma.
Tsurumi H, Hara T, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Shimizu M, Takahashi T, Takami T, Moriwaki H. Tsurumi H, et al. Among authors: kitagawa j. Leuk Lymphoma. 2012 Feb;53(2):247-53. doi: 10.3109/10428194.2011.606383. Leuk Lymphoma. 2012. PMID: 21827339 Clinical Trial.
CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y, Hara T, Kasahara S, Yamada T, Sawada M, Mabuchi R, Matsumoto T, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Kito Y, Goto N, Miyazaki T, Takami T, Takeuchi T, Shimizu M, Tsurumi H. Shibata Y, et al. Among authors: kitagawa j. Hematol Oncol. 2017 Jun;35(2):163-171. doi: 10.1002/hon.2262. Epub 2015 Oct 9. Hematol Oncol. 2017. PMID: 26449182
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T, Hara T, Shibata Y, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Goto N, Kito Y, Kasahara S, Yamada T, Sawada M, Miyazaki T, Takami T, Takeuchi T, Moriwaki H, Tsurumi H. Matsumoto T, et al. Among authors: kitagawa j. Hematol Oncol. 2017 Sep;35(3):288-295. doi: 10.1002/hon.2285. Epub 2016 Mar 21. Hematol Oncol. 2017. PMID: 26999778
165 results